Intravitreal thrombin activity is elevated in retinal vein occlusion
Intravitreal thrombin activity is elevated in retinal vein occlusion
复制标题
视网膜静脉阻塞时玻璃体内凝血酶活性升高
DOI：
10.1097/mbc.0000000000000109
复制
发表时间：
2014
影响因子：
1.1
通讯作者：
M. Koss
中科院分区：
文献类型：
--
作者：
T. Bertelmann;T. Stief;W. Sekundo;S. Mennel;N. Nguyen;M. Koss
评价与健康对照相比，视网膜分支静脉阻塞（BRVO）和视网膜中央静脉阻塞（CRVO）患眼的玻璃体内凝血酶活性是否升高。19例BRVO患者、13例CRVO患者和9例对照受试者的前瞻性临床病例系列。从中央玻璃体中取出玻璃体，立即用200 μ l 5%人白蛋白稳定200 μ l冷冻/解冻的样品，并用200 μ l 2.5mol/l精氨酸（pH8.6）稳定200 μ l其混合物。 凝血酶活性用显色法测定。通过商业荧光酶免疫测定（R&D）测量作为血-视网膜屏障（BRB）破坏的标志物的血管内皮生长因子（VEGF）的玻璃体内水平。BRVO受累眼的玻璃体内凝血酶活性和VEGF水平分别为1.6 ± 1.2 mIU/ml（平均值± SD;范围：0.2-4.2 mIU/ml）和554 ± 568 pg/ml（范围：20-2005 pg/ml），CRVO受累眼为2.6 ± 1.2 mIU/ml（范围：0.8-5.2 mIU/ml）和1332 ± 1350 pg/ml（范围：58-3943 pg/ml），对照眼为0.8 ± 0.8 mIU/ml（范围：0.2-2.7 mIU/ml）和115 ± 120 pg/ml（范围：32-431 pg/ml）。 BRVO、CRVO和对照眼之间玻璃体内凝血酶活性和玻璃体内VEGF水平存在显著差异（P = 0.007和P = 0.003，Kruskal-Wallis检验）。 玻璃体内凝血酶活性与玻璃体内VEGF水平显著相关（r = 0.656; P <0.001，Pearson相关）。 玻璃体内凝血酶活性可能作为一个新的标志物BRB的崩溃或黄斑纤维蛋白沉积在眼科。BRVO、CRVO和健康对照眼之间玻璃体内凝血酶活性的显著差异可能为RVO影响的眼提供新的治疗策略。口服和玻璃体内注射直接凝血酶抑制剂的效果需要在进一步的研究中进行评估。
To evaluate whether intravitreal thrombin activity is elevated in eyes with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in comparison to healthy controls. Prospective clinical case series of 19 patients with BRVO, 13 patients suffering from CRVO and nine participants serving as controls. Vitreous taps were extracted from the central vitreous body, 200 &mgr;l frozen/thawed sample was immediately stabilized with 200 &mgr;l 5% human albumin, and 200 &mgr;l mixture thereof was stabilized with 200 &mgr;l 2.5 mol/l arginine, pH 8.6. Thrombin activity was determined chromogenically. Intravitreal levels of vascular endothelial growth factor (VEGF) as a marker for blood–retina barrier (BRB) breakdown were measured by a commercial chemiluminescent enzyme immuno assay (R&D). Intravitreal thrombin activity and VEGF levels were 1.6 ± 1.2 mIU/ml (mean value ± SD; range: 0.2–4.2 mIU/ml) and 554 ± 568 pg/ml (range: 20–2005 pg/ml) in BRVO-affected eyes, 2.6 ± 1.2 mIU/ml (range: 0.8–5.2 mIU/ml) and 1332 ± 1350 pg/ml (range: 58–3943 pg/ml) in eyes suffering from CRVO as well as 0.8 ± 0.8 mIU/ml (range: 0.2–2.7 mIU/ml) and 115 ± 120 pg/ml (range: 32–431 pg/ml) in controls. There are significant differences of intravitreal thrombin activity and intravitreal VEGF levels between eyes with BRVO, CRVO, and controls (P = 0.007 and P = 0.003, Kruskal–Wallis test). Intravitreal thrombin activity is significantly correlated with intravitreal VEGF levels (r = 0656; P < 0.001, Pearson correlation). Intravitreal thrombin activity might serve as a new marker for BRB breakdown or macular fibrin deposition in ophthalmology. Significant differences of intravitreal thrombin activity between eyes with BRVO, CRVO, and healthy controls might offer new therapeutic strategies for RVO-affected eyes. The effect of oral and intravitrealy injected direct thrombin inhibitors needs to be evaluated in further investigations.
影响因子：
4.4
作者：
Kaneda, Shuzo;Miyazaki, Dai;Inoue, Yoshitsugu
通讯作者：
Inoue, Yoshitsugu